Skip to content

A randomized, controlled trial on the efficacy and safety of anti-HPV biological protein dressing in the treatment of anal canal and perianal condyloma

A randomized, controlled trial on the efficacy and safety of anti-HPV biological protein dressing in the treatment of anal canal and perianal condyloma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17012361
Enrollment
Unknown
Registered
2017-08-14
Start date
2017-09-01
Completion date
Unknown
Last updated
2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condylomata acuminate

Interventions

A:anti-HPV biological protein dressing
B:ALA-PDT

Sponsors

Wuhan 1st Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years; 2. Clinical diagnosis of condyloma acuminata; 3. in the first 2 weeks before admission did not receive other local treatment; 4. in the first 4 weeks before admission did not receive systemic treatment.

Exclusion criteria

Exclusion criteria: 1. In addition to anal canal and perianal condyloma, other parts of patients with condyloma acuminata; 2. Known to suffer from skin light allergy, porphyria patients; 3. Known to the drug and its chemical structure similar drugs are allergic History of the disease; 4. the affected part of the disease may have other effects may affect the evaluation of the disease; 5. scar body; 6. Severe immune dysfunction; 7. suffering from severe visceral systemic disease or pregnant, lactating women; A history of drug abuse.

Design outcomes

Primary

MeasureTime frame
cure rate;recurrence rate;

Secondary

MeasureTime frame
side effect rate;clearance rate of HPV;

Countries

China

Contacts

Public ContactDongsheng Li

Wuhan 1st Hospital

lds1204@126.com+86 13237183940

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026